Surrozen, Inc./DE Derivative Liability
Surrozen, Inc./DE (SRZN) had Derivative Liability of $196.27 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2026-08-06
- 2026-06-30: Derivative Liability $196.27M.
- 2026-03-31: Derivative Liability $235.52M.
- 2025-12-31: Derivative Liability $158.66M.
- 2025-09-30: Derivative Liability $51.65M.
| Period end | Derivative Liability |
|---|---|
| 2026-06-30 | $196.27M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $235.52M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $158.66M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $51.65M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $10.90M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $42.42M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |